Danilo Janjic

Free radical modulation of insulin release in INS-1 cells exposed to alloxan.

Generation of free radicals is thought to mediate the cytotoxic action of alloxan on the pancreatic beta-cell. In this investigation, the early effects of alloxan on cell function were studied. When INS-1D insulinoma cells were exposed to alloxan (1 mM) for 45 min followed by a 3-hr recovery period, the drug increased basal insulin release while abolishing the effect of glucose in static incubations. This was associated with impaired stimulation of cellular metabolism by glucose and reduced viability, both monitored colorimetrically with 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT). These alterations were largely counteracted by the antioxidant butylated hydroxyanisol (BHA). Similar changes occurred when glucose was added directly after 5 min of alloxan treatment, whereas KCl-induced secretion was only partially inhibited. In perifusion, alloxan caused transient insulin secretion to 50% of the rates obtained with glucose 30 min later. Under these conditions, epinephrine abolished the stimulation due to both agents. Membrane potential and cytosolic calcium concentrations ([Ca2+]i) were recorded to clarify the action of alloxan. Alloxan-induced insulin release correlated with depolarization of INS-1D cells and a rise in [Ca2+]i. Alloxan did not augment [Ca2+]i in the presence of BHA or the absence of extracellular calcium. Nickel chloride blocked the effect of alloxan on [Ca2+]i, whereas verapamil was ineffective. This suggests that alloxan promotes Ca2+ influx through channels distinct from L-type channels, perhaps through non-selective cation channels. Thus, alloxan causes changes in INS-1D cells prevented by antioxidant treatment, suggesting that free radicals may modulate the ionic permeability leading to functional activation.

Sites of Action of Trifluoperazine in the Inhibition of Glucose-Stimulated Insulin Release

Trifluoperazine, an inhibitor of calcium-calmodulin functions, was used in an attempt to understand the involvement of calcium-calmodulin in glucose-stimulated insulin release. Isolated rat pancreatic islets were used after a two-day period of maintenance in tissue culture. 45Ca2+ uptake and insulin release were measured during 5-min incubations. Dynamic insulin release and 45Ca2+ efflux were assessed during perifusion of the islets preloaded with 45Ca2+ during the culture period. Both phases of insulin release in response to 16.7 mM glucose were inhibited by approximately 60% in the presence of 10 μM trifluoperazine when the latter was added 35 min prior to high glucose. Stimulation of 45Ca2+ efflux by glucose was abolished. Glucose-stimulated 45Ca2+ uptake was inhibited by 43%. These results were compared with those of experiments in which depolarizing concentrations of potassium (24 mM) were used. Trifluoperazine inhibited K+-stimulated insulin release and 45Ca2+ uptake to a similar extent as that seen with glucose. Trifluoperazine did not appear to interfere with the inhibitory effect of glucose on 45Ca2+ efflux seen in the absence of extracellular Ca2+. Moreover, in Ca2+ deprived medium (with no possibility for Ca2+ uptake) insulin release in response to glucose + ouabain or in response to veratridine was also inhibited by trifluoperazine. It can be speculated that calmodulin is involved in the process by which glucose and potassium stimulate Ca2+ uptake, i.e., by activation of voltage-dependent Ca2+ channels in the plasma membrane. In addition, it appears that calmodulin is involved in the process by which glucose and veratridine act on stored calcium to raise the cytosolic Ca2+ concentration. Finally, trifluoperazine did not inhibit insulin release mediated by cyclic AMP (3-isobutyl-1-methyl-xanthine). Two conclusions may be drawn from this finding: (1) calmodulin may not be involved in the process of exocytosis per se and (2) cyclic AMP and glucose seem to mobilize stored calcium by different mechanisms.

Involvement of Ca2+ in the Impaired Glucose-induced Insulin Release from Islets Cultured at Low Glucose

Islet culture at a low glucose concentration results in a progressive impairment of glucose-induced insulin release. The role of Ca2+ in this defect was studied by comparing rat islets cultured for 6 days either at 8.3 mM (control) or 2.8 mM glucose. For measurement of 45Ca content and 45Ca2+ efflux, islets were kept in the presence of 45Ca2+ throughout. In islets cultured at 8.3 mM glucose, stimulation with 16.7 mM glucose during perifusion caused a typical biphasic pattern of insulin release paralleled by an increase in the rate of 45Ca2+ efflux. Both effects of glucose were markedly reduced in islets kept at 2.8 mM glucose, despite a similar insulin content. Islet 45Ca content was reduced. Both 45Ca content and insulin release were restored when islets were kept for an additional 24 h at 8.3 mM glucose. Insulin release induced by 3-isobutyl-1-methylxanthine (IBMX) or α-ketoisocaproic acid was not impaired, demonstrating that there is no generalized release defect. In contrast, glyceraldehyde- or K+-induced release was decreased. In islets maintained at 2.8 mM glucose, the stimulatory effect of glucose on Ca2+ uptake and the inhibitory effect on Ca2+ efflux (in the absence of Ca2+) were found to be operative. A defect may therefore lie distal to the Ca2+ uptake step involving either the mechanism by which glucose uses cellular Ca or another step yet to be identified.

Phenytoin Inhibition of Insulin Release: Studies on the Involvement of Ca2+ Fluxes in Rat Pancreatic Islets

The mechanism by which phenytoin inhibits insulin release was studied. Insulin release and 45Ca2+ efflux were measured during perifusion of collagenase isolated rat islets after 2-day maintenance in tissue culture in the presence of a trace amount of 45Ca2+. Islets maintained in the absence of the isotope were used to measure 45Ca2+ uptake over 5 min. Glucose (16.7 mM) induced a biphasic release of insulin, which was accompanied by a biphasic increase in the rate of 45Ca2+ efflux above basal. Phenytoin (80 μM) added during second phase rapidly inhibited insulin release. In contrast, phenytoin added together with glucose failed to affect first phase, but reduced second phase release by 64%. Phenytoin failed to affect basal 45Ca2+ efflux in the presence or absence of Ca2+, nor did it interfere with the inhibitory effect of high glucose on Ca2+ efflux. The drug did not affect basal Ca2+ uptake, but significantly reduced glucose-induced Ca2+ uptake. Glucose utilization was not inhibited by phenytoin. It is suggested that phenytoin inhibits glucose-stimulated insulin release by interfering with Ca2+ uptake via voltage-dependent Ca2+ channels. The pattern of inhibition of insulin release appears to favor this conclusion as the second phase is more dependent on the stimulation of Ca2+ uptake than is the first phase.

Calmodulin in various insulin secreting cell types

The involvement of the Ca2+ binding protein, calmodulin, in the regulation of insulin release was studied. Calmodulin was measured in isolated rat islets, rat insulinoma cells, the insulin secreting cell line (RINmSF) and in islets isolated from normal and diabetic Chinese hamsters. Total content of calmodulin was determined by a radioimmunoassay using a rabbit anti-calmodulin serum and was found to lie in the range of 4 to 7 μg/ml protein. When rat islets were maintained in tissue culture for 6 days at 2.8 or 8.3 mM glucose, the content of calmodulin of the two groups was similar. Likewise there was no difference in calmodulin content between islets from normal and diabetic hamsters. This study suggests that a variation of the total cellular calmodulin does not play a role in the process of insulin secretion.